open access

Vol 70, No 2 (2020)
Review article
Published online: 2020-04-07
Get Citation

Adjuvant radioiodine treatment in patients with thyroid cancer – current recommendations

Agnieszka Czarniecka, Daria Handkiewicz-Junak
DOI: 10.5603/NJO.2020.0015
·
Nowotwory. Journal of Oncology 2020;70(2):65-68.

open access

Vol 70, No 2 (2020)
Review article
Published online: 2020-04-07

Abstract

Radioactive iodine therapy (RAI) has been used in patients with differentiated thyroid cancers (DTC) for many decades. However, many changes in thyroid cancer treatment have been introduced for the last decade worldwide, mainly a tendency to deescalate both surgical and adjuvant treatment has been observed. This work summarizes current Polish guidelines for adjuvant radioiodine therapy compared to American Thyroid Association recommendations.

Abstract

Radioactive iodine therapy (RAI) has been used in patients with differentiated thyroid cancers (DTC) for many decades. However, many changes in thyroid cancer treatment have been introduced for the last decade worldwide, mainly a tendency to deescalate both surgical and adjuvant treatment has been observed. This work summarizes current Polish guidelines for adjuvant radioiodine therapy compared to American Thyroid Association recommendations.

Get Citation

Keywords

radioiodine treatment; thyroid cancer

About this article
Title

Adjuvant radioiodine treatment in patients with thyroid cancer – current recommendations

Journal

Nowotwory. Journal of Oncology

Issue

Vol 70, No 2 (2020)

Pages

65-68

Published online

2020-04-07

DOI

10.5603/NJO.2020.0015

Bibliographic record

Nowotwory. Journal of Oncology 2020;70(2):65-68.

Keywords

radioiodine treatment
thyroid cancer

Authors

Agnieszka Czarniecka
Daria Handkiewicz-Junak

References (7)
  1. Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018; 91(1091): 20180136.
  2. Haugen BR, Haugen BR, Alexander EK, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1–133.
  3. Treglia G, Aktolun C, Chiti A, et al. EANM and the EANM Thyroid Committee. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2016; 43(8): 1486–1490.
  4. Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update. Endokrynol Pol. 2018; 69(1): 34–74.
  5. Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019; 29(1): 7–26.
  6. Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. The Lancet Diabetes & Endocrinology. 2018; 6(8): 618–626.
  7. Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2019; 7(1): 44–51.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl